Cytiva Pipe dream to pipeline WP 3

Ocugen’s Stargardt disease therapy trial completes first cohort dosing

The two-phase trial will evaluate the safety of unilateral subretinal administration of OCU410ST in Stargardt disease patients.


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.